Dystonia, Essential Tremor, Holmes Tremor, Huntington's Disease, Movement Disorders, Orofacial Dyskinesias, Parkinson's Disease, Tardive Dyskinesia, Wilson's Disease
Conditions
Brief summary
The proposed study is to evaluate the effectiveness of ExAblate Transcranial MRgFUS as a tool for creating a unilateral lesion in the Vim thalamus or the globus pallidus (GPi) in patients with treatment-refractory symptoms of movement disorders.
Detailed description
The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from movement disorder symptoms: * FUS under MRI-guidance and MRI-based thermometry can be safely delivered to patients suffering from treatment-refractory movement disorders through an intact human skull with a low risk of transient adverse effects as evaluated during follow-up of up to 12-months. * A pre-defined target volume inside the brain can be accurately ablated, as demonstrated on post-treatment MRI. * Lesions generated with ExAblate Neuro will result in clinical effects that are similar to those seen with ablative procedures using other surgical techniques (e.g. RF procedure).
Interventions
DEVICETranscranial ExAblate System
MR Guided Focused Ultrasound
Sponsors
InSightec
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* Men and women, between 18 and 85 years, inclusive. * Subjects who are able and willing to give consent and able to attend all study visits. * A movement disorder symptom that has been deemed treatment-refractory by a movement disorder neurologist, including: o akathisia, akinesia, athetosis, bradykinesia, chorea, dystonia, tremor, myoclonus, dyskinesia, spasms, tics * Medication-refractoriness as determined by an adequate dose and duration of standard movement disorders treatment as determined by a specialist neurologist (e.g. a trial of primidone and propranolol for ET) * Able to communicate sensations during the ExAblate Neuro treatment * Stable doses of all medications for 30 days prior to study entry and for the duration of the study.
Exclusion criteria
* Patients with unstable cardiac status including: * Unstable angina pectoris on medication * Patients with documented myocardial infarction within six months of protocol entry * Congestive heart failure requiring medication (other than diuretic) * Patients on anti-arrhythmic drugs * Severe hypertension (diastolic BP \> 100 on medication) * Patients with standard contraindications for MR imaging such as non-MRI compatible implanted metallic devices including cardiac pacemakers, size limitations, etc. * History of abnormal bleeding and/or coagulopathy (including deep venous thrombosis) * Cerebrovascular disease (multiple CVA or CVA within 6 months) * Symptoms and signs of increased intracranial pressure (e.g. headache, nausea, vomiting, lethargy, and papilledema) * Untreated, uncontrolled sleep apnea * Active or suspected acute or chronic uncontrolled infection * History of intracranial hemorrhage * Individuals who are not able or willing to tolerate the required prolonged stationary supine position during treatment * Are participating or have participated in another clinical trial in the last 30 days * Patients unable to communicate with the investigator and staff. * Presence of any other neurodegenerative disease like multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease. * Patients with a history of seizures within the past year * Patients with psychiatric illness that are not well controlled. Any presence of psychosis will be excluded. * Patients with risk factors for intraoperative or postoperative bleeding (platelet count less than 100,000 per cubic millimeter) or a documented coagulopathy * Patients with brain tumors * Any illness that in the investigator's opinion preclude participation in this study. * Pregnancy or lactation. * Patient is unable to provide his own consent for any reason. * Legal incapacity or limited legal capacity. * Patients who have DBS or a prior stereotactic ablation of the basal ganglia * History of immunocompromise, including patient who is HIV positive * Known life-threatening systemic disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Severity of Device and Procedure Related Complications | At the time of ExAblate procedure | Safety will be evaluated individually for each subject who is treated |
Countries
Canada
Outcome results
None listed